Intuitive SurgicalISRGEarnings & Financial Report
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S.
ISRG Q4 2025 Key Financial Metrics
売上高
$2.9B
粗利益
$1.9B
営業利益
$864.3M
純利益
$794.8M
粗利益率
66.4%
営業利益率
30.2%
純利益率
27.7%
前年比成長
18.8%
EPS
$2.19
資金フロー
Intuitive Surgical Q4 2025 Financial Summary
Intuitive Surgical reported revenue of $2.9B for Q4 2025, with a net profit of $794.8M (27.7% margin). Cost of goods sold was $961.9M, operating expenses totaled $1.0B.
Key Financial Metrics
| Total Revenue | $2.9B |
|---|---|
| Net Profit | $794.8M |
| Gross Margin | 66.4% |
| Operating Margin | 30.2% |
| Report Period | Q4 2025 |
Intuitive Surgical Annual Revenue by Year
Intuitive Surgical annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.1B).
| Year | Annual Revenue |
|---|---|
| 2025 | $10.1B |
| 2024 | $8.4B |
| 2023 | $7.1B |
| 2022 | $6.2B |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $1.89B | $2.01B | $2.04B | $2.41B | $2.25B | $2.44B | $2.51B | $2.87B |
| 前年比成長 | 11.5% | 14.5% | 16.9% | 25.2% | 19.2% | 21.4% | 22.9% | 18.8% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $15.83B | $16.65B | $17.74B | $18.74B | $19.22B | $20.16B | $19.35B | $20.46B |
| 総負債 | $1.78B | $1.85B | $2.07B | $2.21B | $2.01B | $2.21B | $2.31B | $2.52B |
| 株主資本 | $13.96B | $14.71B | $15.58B | $16.43B | $17.11B | $17.85B | $16.93B | $17.82B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $265.4M | $620.5M | $706.5M | $822.6M | $581.6M | $715.4M | $841.0M | $892.5M |
Other Health Care Companies
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
BAX
Baxter International
売上高
$3.0B
純利益
$-1.1B
BDX
Becton Dickinson
売上高
$5.3B
純利益
$382.0M
BSX
Boston Scientific
売上高
$5.3B
純利益
$670.0M
DXCM
Dexcom
売上高
$1.3B
純利益
$267.3M
EW
Edwards Lifesciences
売上高
$1.6B
純利益
$291.1M
GEHC
GE HealthCare
売上高
$5.7B
純利益
$588.0M
HOLX
Hologic
売上高
$1.0B
純利益
$179.1M
IDXX
Idexx Laboratories
売上高
$1.1B
純利益
$274.6M
PODD
Insulet Corporation
売上高
$783.7M
純利益
$101.6M